Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $2.33 and traded as high as $2.43. Vistagen Therapeutics shares last traded at $2.41, with a volume of 65,916 shares trading hands.
Vistagen Therapeutics Stock Down 1.2%
The stock has a market capitalization of $72.73 million, a price-to-earnings ratio of -1.70 and a beta of 0.67. The company's 50-day moving average is $2.31 and its 200-day moving average is $2.60.
Institutional Trading of Vistagen Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. R Squared Ltd acquired a new stake in Vistagen Therapeutics during the fourth quarter worth about $25,000. Cubist Systematic Strategies LLC bought a new position in shares of Vistagen Therapeutics in the first quarter valued at approximately $25,000. Two Sigma Advisers LP acquired a new position in shares of Vistagen Therapeutics during the fourth quarter valued at about $35,000. Man Group plc acquired a new stake in Vistagen Therapeutics during the fourth quarter valued at approximately $54,000. Finally, Bank of America Corp DE increased its holdings in Vistagen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company's stock valued at $62,000 after purchasing an additional 19,331 shares in the last quarter. Hedge funds and other institutional investors own 78.39% of the company's stock.
Vistagen Therapeutics Company Profile
(
Get Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Further Reading
Before you consider VistaGen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VistaGen Therapeutics wasn't on the list.
While VistaGen Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
